Robust Funding for Regenerative Medicine in 2020

The Alliance for Regenerative Medicine has released data on financing for regenerative medicine and it is at a record pace for 2020.  In the first three quarters of 2020, worldwide financing has reached almost $16 billion and exceeded the top prior year of 2018 already ($13.5 billion).  The report includes a breakdown based on amounts for types of regenerative medicine as well as private, public and partnership funding. The report is a short two pages or so and available, here. 

Alliance for Regenerative Medicine: 2019 is Second Best Year in History for Regenerative Medicine Financing

The Alliance for Regenerative Medicine (ARM) has recently released its annual report.  Notably, ARM states that 2019 was the second-best year in history for regenerative medicine financing.  A whopping $9.8 billion US was raised globally.  $7.8 million was raised for gene modified and cell therapy.  Tissue engineering received $442 million.  The report further specifies deals for significant sums as well as public offerings.  The financing numbers are also broken down by type, such as venture capital, with comparison to 2018 and 2017 numbers.  VC financing is up almost a billion dollars in 2019 over 2018.  Financing numbers are also reviewed for the EU and Israel.  The report also specifies that there are 1,066 clinical trials proceeding at the end of 2019.  New approvals and expected approvals are also discussed.